2023-04-24 ノースカロライナ州立大学(NCState)
85%の犬の尿路上皮癌には、BRAFという遺伝子に特定の変異があることが以前の研究で示された。しかし、その他の15%にはどのような変異があるかは分かっていなかった。
この研究では、BRAF V595Eの置換変異がない28例の犬の膀胱がんを調査し、13例に小さな数のヌクレオチドが削除された変異が見つかった。これらの変異は、MAPK経路内の別の重要な遺伝子であるMAP2K1にも生じた。
これらの変異を知ることで、より適切で効果的な治療法を探ることができると期待されている。また、これらのがんを早期に検出するための実験室検査も開発された。
<関連情報>
- https://news.ncsu.edu/2023/04/researchers-identify-a-new-genetic-culprit-in-canine-bladder-cancers/
- https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1010575
BRAF V595E変異を持たないイヌの尿路上皮がんのホールエクソームシーケンス解析: BRAFとMAP2K1の短いインフレーム欠失は、MAPK経路破壊の代替メカニズムを示唆している Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption
Rachael Thomas,Claire A. Wiley,Emma L. Droste,James Robertson,Brant A. Inman,Matthew Breen
PLOS Genetics Published: April 20, 2023
DOI:https://doi.org/10.1371/journal.pgen.1010575
Abstract
Molecular profiling studies have shown that 85% of canine urothelial carcinomas (UC) harbor an activating BRAF V595E mutation, which is orthologous to the V600E variant found in several human cancer subtypes. In dogs, this mutation provides both a powerful diagnostic marker and a potential therapeutic target; however, due to their relative infrequency, the remaining 15% of cases remain understudied at the molecular level. We performed whole exome sequencing analysis of 28 canine urine sediments exhibiting the characteristic DNA copy number signatures of canine UC, in which the BRAF V595E mutation was undetected (UDV595E specimens). Among these we identified 13 specimens (46%) harboring short in-frame deletions within either BRAF exon 12 (7/28 cases) or MAP2K1 exons 2 or 3 (6/28 cases). Orthologous variants occur in several human cancer subtypes and confer structural changes to the protein product that are predictive of response to different classes of small molecule MAPK pathway inhibitors. DNA damage response and repair genes, and chromatin modifiers were also recurrently mutated in UDV595E specimens, as were genes that are positive predictors of immunotherapy response in human cancers. Our findings suggest that short in-frame deletions within BRAF exon 12 and MAP2K1 exons 2 and 3 in UDV595E cases are alternative MAPK-pathway activating events that may have significant therapeutic implications for selecting first-line treatment for canine UC. We developed a simple, cost-effective capillary electrophoresis genotyping assay for detection of these deletions in parallel with the BRAF V595E mutation. The identification of these deletion events in dogs offers a compelling cross-species platform in which to study the relationship between somatic alteration, protein conformation, and therapeutic sensitivity.
Author summary
Several human cancers, including melanoma and colorectal carcinoma, harbor a specific mutation within the BRAF gene, termed V600E. This mutation causes aberrant activation of the MAPK signaling pathway that normally regulates critical processes including cell growth, survival and proliferation. An equivalent mutation occurs in 85% of canine urothelial carcinomas (UC), the most common canine urogenital cancer. We performed DNA sequencing analysis of 28 canine UC cases that do not bear this mutation, to identify alternative mutations that may contribute to tumor development. We identified 13 specimens (46% of cases) harboring short in-frame deletions clustering elsewhere within the BRAF gene, or within MAP2K1, which also functions in the MAPK pathway. Importantly, equivalent deletions also occur in several human cancer subtypes, including certain leukemias and pancreatic carcinomas, and also Langerhans cell histiocytosis, resulting in structural disruption of the associated protein product. Critically, evidence is accumulating from human in vitro studies that tumors with BRAF or MAP2K1 in-frame deletions are susceptible to different classes of small-molecule inhibitors, compared to those with BRAF V600E. Progress has been limited by the relative rarity of the human cancer subtypes in which these aberrations occur. With more than 60,000 dogs developing UC each year in the US, our findings reveal a strategy to overcome these limitations. By performing parallel functional studies of BRAF and MAP2K1 in-frame deletions in canine UC we may greatly expand the volume of biological specimens and clinical data available for elucidating their significance for optimizing treatment protocols in both species.
